



Global  
Antibiotic  
Resistance  
Partnership

# Alert card

(front side)

**CDDEP** THE CENTER FOR  
Disease Dynamics,  
Economics & Policy  
WASHINGTON DC - NEW DELHI



MINISTRY OF HEALTH  
PHARMACY AND POISONS BOARD  
LENANA ROAD, NAIROBI P.O. BOX 27663 - 00506  
TEL: (020) 2716905/6 Ext 114 Fax: (020)-2713431 / 2713409

PV 4

## ADVERSE DRUG REACTION ALERT CARD

PATIENT NAME: .....

AGE: ..... GENDER: .....

DATE ISSUED: ..... ADDRESS: .....

SUSPECTED DRUG(S): .....

DESCRIPTION OF REACTION: .....

Other comments (if any): .....

.....

*Tafadhali hakikisha umebeba kadi hii kila wakati. Kumbuka kumwonyesha mhudumu wa afya kadi hii unapo pata matibabu*

*Please carry this card with you at all times and remember to produce it to your health care professional at each time of consultation.*



# Alert card

(back side)

## **CRITERIA FOR ISSUE OF A PATIENT ALERT CARD**


The criteria for issue of the Patient Alert Card is as follows:

*The alert card is given to:*

- ◆ Patients who are hypersensitive / allergic / intolerant to a particular drug
- ◆ Patients who develop a 'near-fatal' reaction to any particular drug
- ◆ Patients who had a drug- induced morbidity to any drug
- ◆ Patients who had hospital admission due to an ADR to any drug
- ◆ Patients who developed an ADR which caused increase in the health care expenditure





# Pharmacovigilance Curriculum and Implementation Guide





# Pharmacovigilance Trainers Manual and Participants Manual





# Some regulatory aspects arising from pharmacovigilance in Kenya

- Antibiotics
  - Withdrawal – Gatifloxacin
  - Additional warning -box warning for fluoroquinolones
- Other withdrawn products in the market – Rofecoxib, Nimesulide, Lumiracoxib, phenylpropanolamine containing products



# PPB Post-Market Surveillance activities

- ❖ Past:
  - Surveys of medicines to evaluate:  
Range and availability, Registration status with PPB and Quality analysis
  - Antimalarials (baseline pre-ACT, QAMSA), cough and colds, ARV, Anti-TB (research thesis, country-wide)
  
- ❖ Present:
  - Pro-active and reactive surveillance
  - Similar sounding / spelt medicines
  - Drug interactions highlights
  
- ❖ Now and Ahead:
  - Routine PV and PMS of all pharmaceutical products
  - PMS strategy (under development)



# More steps ahead...

- ❖ Developing job aids and IEC materials in preparation of roll-out
- ❖ Sensitize and train field staff across all provinces- for both MoMS and MoPHS
- ❖ Collaboration with KMA, NC, professional societies, stakeholders to encourage reporting of suspected cases
- ❖ Include course on PV at University, Schools and Training Institutions.



# Our pharmacovigilance slogan



*“You need not be certain...  
Just be suspicious”*





# *Our contact ...*

**Department of Pharmacovigilance**  
**Pharmacy and Poisons Board**  
**Lenana Road**

P.O. Box: 27663-00506 Nairobi KENYA

Tel: +254-(020) 3562107

Fax: +254-(020) 2713431 / 2713409

**e-mail:** [pv@pharmacyboardkenya.org](mailto:pv@pharmacyboardkenya.org)

[www.pharmacyboardkenya.org](http://www.pharmacyboardkenya.org)